医薬品リファレンス
Brentuximab
Brentuximab is a medicine in the class oncology. It is used for hodgkin lymphoma.
- 薬効分類: Oncology
- 効能・効果: hodgkin lymphoma
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- 一般的な剤形
- 点滴静注剤
- 一般的な規格
- 50 mg
- 既知の相互作用
- 72 (併用禁忌: 1 · 重大: 7 · 中等度: 47 · 軽度: 17)
- 商品名
- 3
- 国・市場
- 3
何に使われるか
作用のしくみ
CD30-directed antibody-drug conjugate (ADC) consisting of chimeric IgG1 antibody cAC10, specific for human CD30 and the microtubule disrupting agent, monomethyl auristatin E (MMAE, or vedotin). Conjugate binds to cell expressing the CD30 antigen and forms a complex that is internalized within the cell and MMAE is released.
成人の通常用量(添付文書の要約)
Classical Hodgkin Lymphoma: 1.2 mg/kg IV q2Weeks (in combination with AVD); not to exceed 120 mg/dose, Continue until a maximum of 12 doses, disease progression, or unacceptable toxicity
妊娠と授乳
- 妊娠
- Unsafe Antibody-drug conjugate (cytotoxic MMAE): can cause fetal harm. Avoid in pregnancy. Women: effective contraception during treatment and for 2 months after; men with female partners: 4 months.
- 授乳
- Unsafe No human milk data. Avoid breastfeeding during treatment because of possible serious infant harm (low blood counts, nerve or gut toxicity).
報告されている副作用
- Vomiting
- Diarrhea
- Constipation
- Anemia
- Neutropenia
- Pyrexia
注意が必要な方
- Closely monitor for emergence of bacterial, fungal or viral infections
- Acute pancreatitis, including fatal outcomes, reported
- Patients with rapidly proliferating tumor and high tumor burden are at risk of tumor lysis syndrome; closely monitor and treat appropriately
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (72)
- Bleomycin + Brentuximab Contraindicated
- Brentuximab + Dengue vaccine Major
- Brentuximab + Etrasimod Major
- Brentuximab + Idelalisib Major
- Brentuximab + Levoketoconazole Major
- Brentuximab + Nefazodone Major
- Brentuximab + Ritonavir Major
- Brentuximab + Siponimod Major
- Apalutamide + Brentuximab Moderate
- Atazanavir + Brentuximab Moderate
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Brentuximabの完全なモノグラフ(用量、妊娠・授乳、副作用、警告、すべての相互作用)を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Patient counselling points
- Food interactions
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Brentuximab used for?
Brentuximab is a medicine in the class oncology. It is used for Hodgkin lymphoma, Lymphoma.
What side effects have been reported with Brentuximab?
Vomiting, Diarrhea, Constipation, Anemia, Neutropenia, Pyrexia.
Can Brentuximab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Antibody-drug conjugate (cytotoxic MMAE): can cause fetal harm. Avoid in pregnancy. Women: effective contraception during treatment and for 2 months after; men with female partners: 4 months. Breastfeeding: Unsafe. No human milk data. Avoid breastfeeding during treatment because of possible serious infant harm (low blood counts, nerve or gut toxicity).
What does Brentuximab interact with?
MediHelp lists 72 known interactions for Brentuximab. Contraindicated: 1 · Major: 7 · Moderate: 47 · Minor: 17. The most serious include Bleomycin, Dengue vaccine, Etrasimod.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。